Quick Takeaways
- Fairmount Funds Management LLC filed SCHEDULE 13G/A for ENLIVEN THERAPEUTICS, INC. Common Stock, par value $0.001 per share (ELVN).
- Disclosed ownership: 6.3%.
- Date of event: 30 Jun 2025.
Fairmount Funds Management LLC - 30 Jun 2025 SCHEDULE 13G/A Report for ENLIVEN THERAPEUTICS, INC. Common Stock, par value $0.001 per share (ELVN)
- Filing Manager
- Fairmount Funds Management LLC
- Reporting Manager
- Fairmount Funds Management LLC
- Symbol
- ELVN
- Shares outstanding
- 58,911,810 shares
- Disclosed Ownership
- 3,711,444 shares
- Ownership
- 6.3%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Aug 2025, 16:03:22 UTC
- Date of event
- 30 Jun 2025
- Previous filing
- 14 Feb 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Fairmount Funds Management LLC disclosed 6.3% ownership in ENLIVEN THERAPEUTICS, INC. Common Stock, par value $0.001 per share (ELVN) on 30 Jun 2025."
What Changed
- Previous schedule filing date: 14 Feb 2025.
- Current filing was accepted on 14 Aug 2025, 16:03.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 6.3% | 3,711,444 | 0 | 3,711,444 | /s/ Peter Harwin | Peter Harwin, Managing Member | |
| Fairmount Healthcare Fund II L.P. | 6.3% | 3,711,444 | 0 | 3,711,444 | /s/ Peter Harwin | Peter Harwin, Managing Member | |
| Peter Harwin | 6.3% | 3,711,444 | 0 | 3,711,444 | /s/ Peter Harwin | Peter Harwin | |
| Tomas Kiselak | 6.3% | 3,711,444 | 0 | 3,711,444 | /s/ Tomas Kiselak | Tomas Kiselak |